Department of Biochemistry, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
Pharmacol Res. 2020 Sep;159:104988. doi: 10.1016/j.phrs.2020.104988. Epub 2020 Jun 3.
The effect of voglibose on metabolic homeostasis is not well characterized. Therefore, we conducted a systematic review and meta-analysis of clinical trials assessing the effect of voglibose on metabolic profile in patients with type 2 diabetes mellitus (T2DM).
Systematic searches were conducted in PubMed, Scopus, Embase, Google Scholar, Web of Science and Cochrane Library to identify clinical trials assessing the effects of voglibose supplementation on cardio-metabolic profile from incept up to 29 July 2019. Data was pooled using fixed- or random-effect models and weighted mean difference (WMD) as the effect size.
Eight clinical trials from 1094 reports, were eligible for inclusion. Pooled findings identified significant reductions in hemoglobin A1c (HbA1c) (WMD= -0.27; 95 %CI -0.49 to -0.05; P = 0.01; I = 64.8 %) and an increase in LDL-cholesterol levels (WMD=5.97 mg/dl, 95 % CI 0.88, 11.06, P = 0.02; I = 0.0 %). However, no evidence of effect for voglibose intake on T2DM patients was observed for: fasting blood sugar (FBS) (WMD -7.43 mg/dl; 95 %CI -16.56 to 1.71; P = 0.110; I = 69.3 %), serum insulin (WMD= -0.15 μU/mL; 95 %CI -0.89 to 0.60; P = 0.70; I = 0.0 %), total-cholesterol (WMD=2.82 mg/dl, 95 %CI -2.36 to 8.01, P = 0.70; I = 49.7 %), triglycerides (WMD= -7.07 mg/dl, 95 %CI -21.76 to 7.62, P = 0.34; I = 0.0 %), HDL-cholesterol levels (WMD= -2.10 mg/dl, 95 %CI -4.48 to 0.27, P = 0.08; I = 0.0 %,), body mass index (BMI) (WMD=0.09 kg/m, 95 %CI -0.70 to 0.87; P = 0.87; I = 0.0 %), body weight (WMD= -0.42 kg, 95 %CI -0.84 to 0.00; P = 0.05; I = 0.0 %), and adiponectin levels (WMD = 0.32 μg/mL, 95 %CI -0.74 to 1.38; P = 0.55; I = 0.0 %).
The current meta-analysis identified a decrease in HbA1c and an increase in LDL-cholesterol with administration of voglibose. However, no significant effect was observed on FBS, insulin, bodyweight, BMI, adiponectin, triglycerides, total- and HDL-cholesterol levels.
伏格列波糖对代谢稳态的影响尚未得到充分描述。因此,我们进行了一项系统评价和荟萃分析,评估了伏格列波糖对 2 型糖尿病患者代谢谱的影响。
系统检索 PubMed、Scopus、Embase、Google Scholar、Web of Science 和 Cochrane Library,以确定截至 2019 年 7 月 29 日评估伏格列波糖补充剂对心脏代谢谱影响的临床试验。使用固定或随机效应模型和加权均数差(WMD)作为效应量进行数据合并。
从 1094 份报告中筛选出 8 项符合纳入标准的临床试验。汇总分析结果表明,血红蛋白 A1c(HbA1c)显著降低(WMD=-0.27;95%CI -0.49 至 -0.05;P=0.01;I=64.8%),LDL-胆固醇水平升高(WMD=5.97mg/dl,95%CI 0.88 至 11.06,P=0.02;I=0.0%)。然而,伏格列波糖摄入对 2 型糖尿病患者的空腹血糖(FBS)(WMD=-7.43mg/dl;95%CI -16.56 至 1.71;P=0.110;I=69.3%)、血清胰岛素(WMD=-0.15μU/mL;95%CI -0.89 至 0.60;P=0.70;I=0.0%)、总胆固醇(WMD=2.82mg/dl,95%CI -2.36 至 8.01,P=0.70;I=49.7%)、三酰甘油(WMD=-7.07mg/dl,95%CI -21.76 至 7.62,P=0.34;I=0.0%)、高密度脂蛋白胆固醇(WMD=-2.10mg/dl,95%CI -4.48 至 0.27,P=0.08;I=0.0%)、体重指数(WMD=0.09kg/m,95%CI -0.70 至 0.87;P=0.87;I=0.0%)、体重(WMD=-0.42kg,95%CI -0.84 至 0.00;P=0.05;I=0.0%)和脂联素水平(WMD=0.32μg/mL,95%CI -0.74 至 1.38;P=0.55;I=0.0%)均无显著影响。
本荟萃分析确定了伏格列波糖可降低 HbA1c 并升高 LDL-胆固醇水平。然而,FBS、胰岛素、体重、BMI、脂联素、三酰甘油、总胆固醇和 HDL-胆固醇水平无显著变化。